Clinical Trials Browser

Active not recruiting × apalutamide × 90 days × Clear all

NCT02257736 2026-03-19

An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

Phase 3 Active not recruiting

982 enrolled 15 charts

Prostatic Neoplasms

NCT02531516 2026-03-19

An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT03412396 2026-03-19

Apalutamide in Treating Patients With Prostate Cancer Before Radical Prostatectomy

Phase 2 Active not recruiting

45 enrolled 10 charts

Prostatic Neoplasms

NCT04530552 2026-03-19

Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland

Phase 2 Active not recruiting

34 enrolled 11 charts

Prostatic Neoplasms

NCT04108208 2026-03-16

A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)

Phase 4 Active not recruiting

75 enrolled 9 charts

Prostatic Neoplasms

NCT03523442 2026-03-13

A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Cancer

Phase 1 Active not recruiting

Prostatic Neoplasms

NCT04557059 2026-03-13

PRIMORDIUM

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT04662580 2026-03-13

ARX517

Phase 1 Active not recruiting

Prostatic Neoplasms

NCT05901649 2026-03-13

ArtemisPRO

Active not recruiting

Metastatic Hormone-sensitive Prostate Cancer

NCT05884398 2026-03-12

LIBERTAS

Phase 3 Active not recruiting

Metastatic Castrate-sensitive Prostate Cancer

NCT05960578 2026-03-12

Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT02703623 2026-03-06

Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT04325828 2026-02-13

YATAGARASU

Phase 2 Active not recruiting

31 enrolled 15 charts

Salivary Gland Neoplasms

NCT03902951 2026-02-05

Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT01946204 2026-02-02

SPARTAN

Phase 3 Active not recruiting

1,207 enrolled 15 charts 1 FDA

Prostatic Neoplasms

NCT02489318 2026-02-02

TITAN

Phase 3 Active not recruiting

1,052 enrolled 13 charts 1 FDA

Prostatic Neoplasms

NCT06734130 2026-01-21

Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT04267887 2026-01-20

Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT03767244 2026-01-16

PROTEUS

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT04513717 2026-01-14

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT02949284 2026-01-07

Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery

Phase 2 Active not recruiting

Stage II Prostate Adenocarcinoma